INNOVIVA, INC. (INVA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $727.00K; Additional Paid in Capital, Common StockUSD $859.99M; Treasury Stock, Common, ValueUSD (m).
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $738.00K; Additional Paid in Capital, Common StockUSD $884.95M; Treasury Stock, Common, ValueUSD (m).
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $747.00K; Additional Paid in Capital, Common StockUSD $902.73M; Treasury Stock, Common, ValueUSD (m).
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $748.00K; Additional Paid in Capital, Common StockUSD $903.99M; Treasury Stock, Common, ValueUSD (m).
INNOVIVA, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Common, Value USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Common, Shares shares | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Common Stock, Value, Outstanding USD | Treasury Stock, Retired, Cost Method, Amount USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Treasury Stock, Number of Shares Held (Deprecated 2016-01-31) shares | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $727.00K | $859.99M | (m) | $372.54M | $1.23B | $1.23B | (m) | (m) | (m) | 3 month · $4.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $738.00K | $884.95M | (m) | $455.96M | $1.34B | $1.34B | (m) | (m) | (m) | 3 month · $2.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $747.00K | $902.73M | (m) | $269.37M | $1.17B | $1.17B | (m) | (m) | (m) | 12 month · $9.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $748.00K | $903.99M | (m) | $105.22M | (m) | $1.01B | (m) | (m) | (m) | 3 month · $2.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $630.00K | $698.88M | (m) | $15.31M | (m) | $714.82M | (m) | (m) | (m) | 3 month · $2.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $628.00K | $694.66M | (m) | $-48.38M | (m) | $646.90M | (m) | (m) | (m) | 3 month · $2.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $627.00K | $692.33M | $0.00 | $-1.80M | $691.16M | $691.16M | 0.00 | (m) | (m) | 12 month · $6.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $626.00K | $690.04M | $0.00 | $-22.13M | (m) | $668.54M | 0.00 | (m) | (m) | 3 month · $1.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $626.00K | $688.23M | $0.00 | $-23.34M | (m) | $665.51M | 0.00 | (m) | 3 month · $5.26M | 3 month · $1.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $628.00K | $1.09B | $393.83M | $11.34M | (m) | $703.68M | 32.01M | (m) | 3 month · $9.66M | 3 month · $1.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $633.00K | $1.09B | $393.83M | $-25.19M | (m) | $674.96M | 32.01M | (m) | 12 month · $76.48M | 12 month · $5.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $644.00K | $1.11B | $393.83M | $-86.72M | (m) | $627.49M | 32.01M | (m) | 3 month · $11.07M | 3 month · $1.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $653.00K | $1.12B | $393.83M | $-168.77M | (m) | $555.09M | 32.01M | (m) | 3 month · $9.29M | 3 month · $1.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $659.00K | $1.12B | $393.83M | $-170.05M | (m) | $561.49M | 32.01M | (m) | 3 month · $40.73M | 3 month · $1.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $692.00K | $1.16B | $393.83M | $-204.91M | $565.79M | $565.79M | 32.01M | 12 month · $-16.59M | 12 month · $8.50M | 12 month · $7.35M | 12 month · $3.00K | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2022-09-30 | $0.00 | $698.00K | $1.17B | $393.83M | $-136.60M | $641.37M | $641.37M | 32.01M | (m) | (m) | 3 month · $3.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $697.00K | $1.18B | $393.83M | $-402.20M | $388.34M | $565.46M | 32.01M | (m) | (m) | 3 month · $1.35M | 3 month · $3.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $696.00K | $1.18B | $393.83M | $-403.14M | $386.64M | $552.22M | 32.01M | 3 month · $-16.59M | (m) | 3 month · $954.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $696.00K | $1.26B | $393.83M | $-456.15M | $414.74M | $525.93M | 32.01M | (m) | 12 month · $394.15M | 12 month · $2.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2021-09-30 | $0.00 | $695.00K | $1.26B | $393.83M | $-466.49M | $402.81M | $491.81M | 32.01M | (m) | (m) | 3 month · $542.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $0.00 | $695.00K | $1.26B | $393.83M | $-538.93M | $329.78M | $393.75M | 32.01M | (m) | 3 month · $394.15M | 3 month · $470.00K | (m) | (m) | (m) | (m) | (m) | 3 month · $8.00K | (m) | (m) | (m) | (m) |
| 2021-03-31 | $0.00 | $1.01M | $1.26B | (m) | $-627.88M | $634.46M | $696.68M | (m) | (m) | (m) | 3 month · $451.00K | (m) | (m) | (m) | (m) | (m) | 3 month · $8.00K | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $1.01M | $1.26B | $0.00 | $-722.00M | $539.91M | $607.84M | 0.00 | (m) | (m) | 12 month · $1.70M | (m) | (m) | $0.00 | (m) | (m) | 12 month · $366.00K | (m) | 12 month · $27.00K | (m) | (m) |
| 2020-09-30 | $0.00 | $1.01M | $1.26B | (m) | $-775.90M | $485.56M | $534.87M | (m) | (m) | (m) | 3 month · $441.00K | (m) | (m) | $0.00 | (m) | (m) | 3 month · $8.00K | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $1.01M | $1.26B | (m) | $-804.12M | $456.91M | $492.81M | (m) | (m) | (m) | 3 month · $375.00K | (m) | (m) | $-2.00K | (m) | (m) | 3 month · $350.00K | (m) | (m) | (m) | (m) |
| 2020-03-31 | $0.00 | $1.01M | $1.26B | (m) | $-880.97M | $379.54M | $405.87M | (m) | (m) | (m) | 3 month · $435.00K | (m) | (m) | $33.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $1.01M | $1.26B | (m) | $-946.40M | $313.50M | $342.12M | (m) | (m) | (m) | 12 month · $2.06M | (m) | (m) | $27.00K | (m) | (m) | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2019-09-30 | $0.00 | $1.01M | $1.26B | (m) | $-992.35M | $267.06M | $283.76M | (m) | (m) | (m) | 3 month · $489.00K | (m) | (m) | $25.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $0.00 | $1.01M | $1.26B | (m) | $-1.03B | $226.68M | $246.70M | (m) | (m) | (m) | 3 month · $474.00K | (m) | (m) | $33.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $0.00 | $1.01M | $1.26B | (m) | $-1.07B | $188.25M | $199.94M | (m) | (m) | (m) | 3 month · $605.00K | (m) | (m) | $10.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $1.01M | $1.26B | $0.00 | $-1.10B | $153.58M | $159.05M | (m) | (m) | (m) | 12 month · $3.23M | (m) | (m) | $-3.00K | (m) | 12 month · $0.00 | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2018-09-30 | (m) | $1.01M | $1.26B | $3.26M | $-1.37B | $-111.36M | $-108.28M | 150.00K | (m) | (m) | 3 month · $-874.00K | (m) | (m) | $-3.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $1.01M | $1.26B | $3.26M | $-1.41B | $-157.36M | $-155.36M | 150.00K | (m) | (m) | 3 month · $1.45M | (m) | (m) | $-10.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.01M | $1.26B | $3.26M | $-1.47B | $-213.56M | $-212.75M | 150.00K | (m) | (m) | 3 month · $2.17M | (m) | (m) | $-22.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.02M | $1.26B | $3.26M | $-1.50B | $-242.86M | $-242.71M | 150.00K | 12 month · $65.36M | (m) | 12 month · $9.83M | (m) | (m) | $-18.00K | (m) | (m) | 12 month · $23.00K | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.08M | $1.34B | $3.26M | $-1.56B | $-222.96M | (m) | 150.00K | (m) | (m) | (m) | (m) | (m) | $-3.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $1.09M | $1.29B | $3.26M | $-1.58B | $-296.73M | (m) | 150.00K | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $1.09M | $1.28B | $3.26M | $-1.62B | $-334.19M | (m) | 150.00K | (m) | (m) | (m) | (m) | (m) | $-1.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.08M | $1.28B | $3.26M | $-1.63B | $-352.99M | $-352.99M | 150.00K | (m) | (m) | 12 month · $8.30M | (m) | (m) | $1.00K | (m) | (m) | (m) | 12 month · 10.84 | (m) | (m) | (m) |
| 2016-09-30 | (m) | $1.10M | $1.29B | $3.26M | $-1.66B | $-367.86M | (m) | 150.00K | (m) | (m) | (m) | (m) | (m) | $8.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $1.12M | $1.31B | (m) | $-1.67B | $-363.10M | (m) | (m) | (m) | (m) | (m) | (m) | $3.26M | $6.00K | (m) | (m) | (m) | (m) | (m) | 150.00K | (m) |
| 2016-03-31 | (m) | $1.13M | $1.33B | (m) | $-1.69B | $-361.97M | (m) | (m) | (m) | (m) | (m) | (m) | $3.26M | $-1.00K | (m) | (m) | (m) | (m) | (m) | 150.00K | (m) |
| 2015-12-31 | (m) | $1.15M | $1.35B | $3.26M | $-1.69B | $-342.64M | $-342.64M | 150.00K | (m) | (m) | 12 month · $6.87M | (m) | $3.26M | $-2.00K | (m) | (m) | (m) | 12 month · 9.95 | (m) | 150.00K | 150.00K |
| 2015-09-30 | (m) | (m) | $1.38B | (m) | $-1.70B | $-323.00M | (m) | (m) | (m) | (m) | (m) | (m) | $3.26M | $11.00K | $1.18M | (m) | (m) | (m) | (m) | 150.00K | (m) |
| 2015-06-30 | (m) | (m) | $1.40B | (m) | $-1.69B | $-293.99M | (m) | (m) | (m) | (m) | (m) | (m) | $3.26M | $-10.00K | $1.17M | (m) | (m) | (m) | (m) | 150.00K | (m) |
| 2015-03-31 | (m) | $1.17M | $1.43B | (m) | $-1.68B | $-260.14M | (m) | (m) | (m) | (m) | (m) | (m) | $3.26M | $-12.00K | (m) | (m) | (m) | (m) | (m) | 150.00K | (m) |
| 2014-12-31 | (m) | $1.16M | $1.45B | (m) | $-1.67B | $-223.35M | $-223.35M | (m) | (m) | (m) | 12 month · $27.48M | (m) | $3.26M | $-87.00K | $1.16M | (m) | (m) | (m) | (m) | 150.00K | 150.00K |
| 2014-09-30 | (m) | $1.15M | $1.47B | (m) | $-1.66B | $-193.14M | (m) | (m) | (m) | (m) | (m) | (m) | $3.26M | $-197.00K | (m) | (m) | (m) | (m) | (m) | 150.00K | (m) |
| 2014-06-30 | (m) | $1.13M | $1.44B | (m) | $-1.64B | $-187.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.12M | $1.83B | (m) | $-1.57B | $263.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $171.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $1.11M | $1.80B | (m) | $-1.51B | $299.12M | (m) | (m) | (m) | (m) | 12 month · $25.86M | (m) | $0.00 | $162.00K | $1.11M | (m) | (m) | (m) | (m) | 0.00 | 0.00 |
| 2013-09-30 | (m) | $1.10M | $1.78B | (m) | $-1.46B | $330.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $202.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.01M | $1.49B | (m) | $-1.41B | $85.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-15.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $993.00K | $1.46B | (m) | $-1.37B | $91.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $92.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $984.00K | $1.49B | (m) | $-1.33B | $155.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $99.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $979.00K | $1.48B | (m) | $-1.30B | $173.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $116.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $969.00K | $1.46B | (m) | $-1.27B | $189.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-109.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $865.00K | $1.24B | (m) | $-1.23B | $6.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-9.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $855.00K | $1.23B | (m) | $-1.32B | $-87.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $16.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | $1.22B | (m) | $-1.28B | $-59.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $16.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $1.21B | (m) | $-1.25B | (m) | $-37.48M | (m) | (m) | (m) | (m) | (m) | (m) | $-8.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $1.18B | (m) | $-1.20B | $-22.42M | $-22.42M | (m) | (m) | (m) | (m) | (m) | (m) | $33.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $-188.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $-134.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |